Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,213 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (double-blind) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

NCT01951560
View directory record Official record
Conditions
Shock,Hemorrhagic
Interventions
Valproic Acid, Isotonic saline solution
Drug
Lead sponsor
Dr. Hasan Alam
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

NCT05756920
View directory record Official record
Conditions
Healthy
Interventions
ABL301, Placebo
Drug
Lead sponsor
ABL Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sublingual Immunotherapy in Peanut-allergic Children

NCT00597727
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut SLIT, Placebo SLIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 2 Interventional

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

NCT00103727
View directory record Official record
Conditions
Schizophrenia
Interventions
Talnetant, placebo, risperidone
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
22
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 17, 2026, 10:39 PM EDT
Terminated Phase 4 Interventional Results available

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT03633227
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Rialto, California • Sacramento, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 17, 2026, 10:39 PM EDT
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome (FCS)
Interventions
LCQ908, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seatlle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Not applicable Interventional Results available

Placebo Controlled Trial of Botulinum Toxin for Gastroparesis

NCT00372970
View directory record Official record
Conditions
Gastroparesis
Interventions
Botulinum toxin A, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00137969
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

NCT03941483
View directory record Official record
Conditions
Acute Kidney Injury (AKI)
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
35 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

NCT03764618
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Not applicable Interventional Results available

Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT

NCT00285818
View directory record Official record
Conditions
Depression
Interventions
Mifepristone, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Constipation Fiber Trial

NCT02193997
View directory record Official record
Conditions
Functional Constipation in Children
Interventions
Fiber, Placebo
Other
Lead sponsor
Warren Bishop
Other
Eligibility
2 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 4 Interventional

Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension

NCT00419796
View directory record Official record
Conditions
Osteoarthritis With Controlled Hypertension
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Sep 17, 2026, 10:39 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

NCT03273062
View directory record Official record
Conditions
Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions
Tolcapone 200 MG, Placebo
Drug · Other
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 17, 2026, 10:39 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 17, 2026, 10:39 PM EDT
Terminated Phase 2 Interventional

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

NCT02484703
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RO5186582
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 17, 2026, 10:39 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373
View directory record Official record
Conditions
VEXAS, VEXAS Syndrome
Interventions
Pacritinib, Placebo
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT04594369
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
12 Years to 85 Years
Enrollment
1,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
67
States / cities
Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 10:39 PM EDT
Recruiting Not applicable Interventional

Nicotinamide Riboside Clinical Trial for GWI

NCT05243290
View directory record Official record
Conditions
Gulf War Illness
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Roskamp Institute Inc.
Other
Eligibility
47 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 17, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 17, 2026, 10:39 PM EDT